Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Johnson & Johnson (J&J)

Status and phase: Terminated; Phase 3

Conditions: Anemia

Treatments: Drug: epoetin alfa

Study type: Interventional

Funder types: Industry

Identifiers

NCT00083486

CR010939

EPO-CAN-203

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Body weight >/=99 lbs
• ECOG 0-2
• Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
• Screening hemoglobin level of </=11.0 g/dL for men or </=10.0 for women